



Resource impact template

Resource impact

Published: 4 December 2024

Last updated: 4 December 2024

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for wet age-related macular degeneration:

- [Bevacizumab gamma for treating wet age-related macular degeneration](#) (2024) NICE technology appraisal guidance 1022
- [Faricimab for treating wet age-related macular degeneration](#) (2022) NICE technology appraisal guidance 800
- [Brolucizumab for treating wet age-related macular degeneration](#) (2021) NICE technology appraisal guidance 672
- [Aflibercept solution for injection for treating wet age-related macular degeneration](#) (2013) NICE technology appraisal guidance 294
- [Ranibizumab and pegaptanib for the treatment of age-related macular degeneration](#) (2008) NICE technology appraisal guidance 155